Luther King Capital Management (LKCM)
IOVA icon

Luther King Capital Management (LKCM)’s Iovance Biotherapeutics IOVA Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-114,210
Closed -$2.97M – 610
2021
Q2 		$2.97M Buy
114,210
+23,365
+26% +$607K 0.01% 272
2021
Q1 		$2.88M Buy
90,845
+33,815
+59% +$1.4M 0.02% 253
2020
Q4 		$2.65M Buy
+57,030
New +$2.26M 0.01% 252

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Luther King Capital Management (LKCM)'s IOVA Position: Q3 2021 in Review

Luther King Capital Management (LKCM) sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 114,210 shares — an estimated $2.97M sold.

Luther King Capital Management (LKCM) first reported a position in IOVA in Q4 2020 and held it in 3 quarters. The position peaked at $2.97M in Q2 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Luther King Capital Management (LKCM) reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 114,210 Iovance Biotherapeutics shares in Q3 2021, an estimated $2.97M.
  • Luther King Capital Management (LKCM) first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 3 quarters.
  • Luther King Capital Management (LKCM)'s Iovance Biotherapeutics position peaked at $2.97M in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q3 2021, filed 10 Nov 2021.